drugset / Trial / NCT02081443

In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients

NCT02081443

RandomizedParallel-groupOpen-labelOther

Summary

Cangrelor is a potent intravenous P2Y12 receptor inhibitor with rapid onset and offset of action associated with a greater reduction in ischemic events, including stent thrombosis, in patients undergoing stent procedures who have not been pretreated with clopidogrel. In vitro investigations have shown cangrelor to be associated with more rapid, potent, and consistent platelet inhibition in patients on maintenance prasugrel therapy exposed to a re-loading dose of prasugrel. However, if cangrelor exerts similar effects in ticagrelor treated patients remain unknown. The aim of the present study is to evaluate the effects on platelet function achieved after in vitro incubation with cangrelor in patients on ticagrelor maintenance dose who receive a loading dose of ticagrelor.

Timeline

Start
2014-04
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ticagrelor Small molecule 90 mg Oral
Comparator Ticagrelor Small molecule 180 mg Oral